Chimelrule

We’re pleased to share that Belite Bio received Orphan Drug Status for tinlarebant in Stargardt disease (STGD1) in Switzerland. #StargardtDisease #BeliteBio Learn more: investors.belitebio.com/news-releases/…

@belite_bio Congrats!!🎉

We initiated a rolling NDA submission to the U.S. FDA for our investigational oral therapy for Stargardt disease type 1. Learn more: investors.belitebio.com/news-releases/…

Belite Bio initiated a rolling New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for tinlarebant, an investigational oral therapy targeting Stargardt disease type 1 (STGD1) hubs.li/Q04dJDmV0

Big milestone for Belite Bio 🚀 They’ve announced the start of a rolling NDA submission for Tinlarebant - a key step toward potential approval. Details here: investors.belitebio.com/news-releases/…

@KubotaPharma so what are the steps to get it in Europe? any contacts ?

【当社を応援してくださっている皆様】 パリで新たな一歩 ― 「エミクススタト塩酸塩」供給・ライセンス契約締結と調印式｜窪田製薬HD note.com/kubota_holding… #スターガルト病#希少網膜疾患#エミクススタト塩酸塩#コンパッショネートユース#窪田製薬#KubotaVision#KÔL

Results of a multicenter controlled clinical trial of the photovoltaic retina implant microarray (PRIMA, Science Corporation) system showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12. hubs.li/Q042gwNT0

“We found that patients [in clinical trials] were able to regain the ability to read – not fast, not quickly, but they really could start to read again using a retinal prosthesis.” Frank Brodie, MD, Science’s Medical Director for Vision and PRIMA, joined @_BrightFocus to discuss the PRIMA brain-computer interface (BCI) retinal implant, the first treatment shown in clinical trials to restore functional vision for geographic atrophy due to AMD. Listen to the entire discussion here: brightfocus.org/resource/can-r…

@ScienceCorp_ @OphthTimes @NEJM congrats, question is when it will be available to patients

.@OphthTimes reports on a @NEJM editorial describing our PRIMA retinal implant as “the first treatment to restore vision” in clinical trials for certain patients with advanced geographic atrophy associated with age-related macular degeneration. ophthalmologytimes.com/view/prima-ret…

@RetinaToday Would be amazing to get the same pipeline poster for stargardt disease

Want to stay on top of AMD research? The annual interactive pipeline poster is now live! ow.ly/8Uht50XWiOt ✨ Updated therapies 📊 New data 🔬 WNT + AREDS/GA discussions From Retina Today + Peter Kaiser, MD #retina

Anyone attending #AlkeusPharma presentation at #JPM2026 ? There’s no webcast unfortunately

@drsmusunuri Awesome, what are the next steps?

It is exciting to share 12-month results from the Phase 1 GARDian1 trial for #OCU410ST in individuals with early to advanced Stargardt disease, where no treatment currently exists. #Biotech

@FasserChristina An interesting question is how long it will take to move from approval in adolescents to approval in adults, and what steps are required along the way- for example, conducting a pivotal study, relying on off-label prescribing, and other regulatory measures.

Tinlarebant reduces lesion growth rate in Stargardt disease healio.com/news/ophthalmo…

🔴Today, Belite Bio reported positive topline Phase 3 DRAGON results for Tinlarebant — the first therapeutic candidate to demonstrate efficacy in a global Phase 3 trial in Stargardt disease. Learn more: investors.belitebio.com/news-releases/…

🚨 Breakthrough alert: A new study in the @NEJM reports that the PRIMA subretinal implant helped restore meaningful central vision in ~80% of participants with advanced geographic atrophy (an untreatable form of #AMD). nejm.org/doi/10.1056/NE… #BionicVision #NeuroTech

@OphthTimes Did #AlkeusPharma say anything about their plan to submit NDA? On their website they used to say “by the end of 2024” and then “as soon as possible in 2025”

Philip Ferrone, MD, discussed the safety and efficacy of oral gildeuretinol in participants with intermediate-stage Stargardt disease during his interview at the 2025 AAO meeting. Watch our website for the video coming soon!

Anyone attended #AlkeusPharma presentation this morning? #AAO2025

We are pleased to share that results from the clinical study of our investigational therapy in moderate Stargardt disease (TEASE-2) will be presented during Retina Subspecialty Day at AAO on Saturday, October 18. alkeuspharma.com/news/ #AlkeusPharma #AAO2025 #Retina

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant $BLTE tinyurl.com/26hnx36w

@reVisiontx are you guys still active? you haven’t communicated for a while!

Today is Seeing Eye Guide Dog Anniversary, where #TheSeeingEye celebrates 95 years of service. Learn more at our LinkedIn page. #DEI #EqualAccessibility #VisuallyImpaired #Support linkedin.com/company/revisi…